Top

Published in:

Open Access 01-12-2010 | Original Paper

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture

Authors: Valerie Trapp, Basmina Parmakhtiar, Vartan Papazian, Lyndsay Willmott, John P. Fruehauf

Published in: Angiogenesis | Issue 4/2010

Abstract

Resveratrol, a naturally occurring polyphenol, has been reported to be an anti-tumor and chemopreventive agent. Recent data show that it may also exert anti-angiogenic effects. We hypothesized that the anti-angiogenic activity of resveratrol may be caused by modulation of tumor cell release of thrombospondin-1 (TSP1) and vascular endothelial growth factor (VEGF) into the extracellular matrix, leading to vascular endothelial cell (VEC) apoptosis. We therefore evaluated the effects of resveratrol on melanoma cell lines co-cultured with vascular endothelial cells in monolayer and in three dimensional spheroids. We found that resveratrol stimulated isolated VEC proliferation, while it caused growth inhibition of VECs grown with melanoma cells in three-dimensional co-culture. This effect was associated with increased melanoma cell expression of tumor suppressor protein 53 and matrix protein TSP1, as well as decreased hypoxia-driven expression of hypoxia inducible factor-1α and inhibition of VEGF production.

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324(1):1–8CrossRefPubMed

Weidner N (2000) Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 31(4):403–405CrossRefPubMed

Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3(6):401–410CrossRefPubMed

Cao Y (2005) Tumor angiogenesis and therapy. Biomed Pharmacother 59(Suppl 2):S340–S343CrossRefPubMed

Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, Harris AL (1997) Targeting gene expression to hypoxic tumor cells. Nat Med 3(5):515–520CrossRefPubMed

Fruehauf JP, Meyskens FL Jr (2007) Reactive oxygen species: a breath of life or death? Clin Cancer Res 13(3):789–794CrossRefPubMed

Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ, Williams KJ (2006) Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 69(2):411–418CrossRefPubMed

Mazure NM, Chen EY, Laderote KR, Giaccia AJ (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90(9):3322–3331PubMed

Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ (2005) Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res 65(11):4775–4781CrossRefPubMed

10.

Darland DC, D’Amore PA (1999) Blood vessel maturation: vascular development comes of age. J Clin Invest 103(2):157–158CrossRefPubMed

11.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13(1):9–22PubMed

12.

Toi M, Hoshina S, Takayanagi T, Tominaga T (1994) Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 85(10):1045–1049PubMed

13.

Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80(1):98–106CrossRefPubMed

14.

Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74(1):64–68CrossRefPubMed

15.

Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P, Aubin F (2005) Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol 152(4):685–689CrossRefPubMed

16.

An WG, Kenekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM (1998) Stabilization of wild-type p53 by hypoxia-inducible factor 1α. Nature 392:405–408CrossRefPubMed

17.

Hansson LO, Friedler A, Freund S, Rudiger S, Fersht AR (2002) Two sequence motifs from HIF1α bind to the DNA-binding site on p53. PNAS 99(16):10305–10309CrossRefPubMed

18.

Sanchez-Puig N, Veprintsev DB, Fersht AR (2005) Binding of natively unfolded HIF1α ODD domain to p53. Mol Cell 17:11–21CrossRefPubMed

19.

Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ Jr, Giaccia AJ (1994) Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 14(9):6264–6277PubMed

20.

Wenger Rh, Camenisch G, Desbaillets I, Chilov D, Gassmann M (1998) Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 58:5678–5680PubMed

21.

Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265(5179):1582–1584CrossRefPubMed

22.

Tokunaga T, Nakamura M, Oshika Y, Tsuchida T, Kazuno M, Fukushima Y, Kawai K, Abe Y, Kijima H, Yamazaki H, Tamaoki N, Ueyama Y (1998) Alterations in tumor suppressor gene p53 correlate with inhibition of thrombospondin-1 gene expression in colon cancer cells. Virchows Arch 433:415–418CrossRefPubMed

23.

Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD (1999) Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100:1423–1431PubMed

24.

Guo N, Krutzsch HC, Inman JK, Roberts DD (1997) Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735–1742PubMed

25.

Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B, Martiny L (2004) Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49:245–258CrossRefPubMed

26.

Grant SW, Kyshtoobayeva AS, Kurosaki T, Jakowatz J, Fruehauf JP (1998) Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma. Cancer Detect Prev 22(3):185–194CrossRefPubMed

27.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE (2005) The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11(10):3733–3742CrossRefPubMed

28.

Mehta R, Kyshtoobayeva A, Kurosaki T, Kim H, Stroup R, McLaren CE, Li KT, Fruehauf JP (2001) Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 7(1):81–88PubMed

29.

Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15(16):1889–1893CrossRefPubMed

30.

Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc Natl Acad Sci USA 106(16):6591–6596CrossRefPubMed

31.

Larsen M, Høg A, Lund EL, Kristjansen PE (2005) Interactions between HIF-1 and Jab1: balancing apoptosis and adaptation. Outline of a working hypothesis. Adv Exp Med Biol 566:203–211CrossRefPubMed

32.

Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG (2009) p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 284(17):11171–11183CrossRefPubMed

33.

Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6(12):909–923CrossRefPubMed

34.

Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J Biol Chem 273(49):33048–33053CrossRefPubMed

35.

Box NF, Terzian T (2008) The role of p53 in pigmentation, tanning, and melanoma. Pigment Cell Melanoma Res 21(5):525–533CrossRefPubMed

36.

Lavin MF, Gueven N (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13(6):941–950CrossRefPubMed

37.

Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90(4):595–606CrossRefPubMed

38.

Brakenhielm E, Cao R, Cao Y (2001) Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 15(10):1798–1800PubMed

39.

Olas B, Wachowicz B (2002) Resveratrol and vitamin C as antioxidants in blood platelets. Thromb Res 106(2):143–148CrossRefPubMed

40.

Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220CrossRefPubMed

41.

Kundu JK, Surh YJ (2004) Molecular basis of chemoprevention by resveratrol: NF-kB and AP-1 as potential targets. Mutat Res 555(1–2):65–80PubMed

42.

Clément MV, Hirpara JL, Chawdhury SH, Pervaiz S (1998) Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92(3):996–1002PubMed

43.

Huang C, Ma WY, Goranson A, Dong Z (1999) Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20(2):237–242CrossRefPubMed

44.

Mgbonyebi OP, Russo J, Russo IH (1998) Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12(4):865–869PubMed

45.

Hsieh TC, Wu JM (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249(1):109–115CrossRefPubMed

46.

Chen JC, Chen Y, Lin JH, Wu JM, Tseng SH (2006) Resveratrol suppresses angiogenesis in gliomas: evaluation by color Doppler ultrasound. Anticancer Res 26(2A):1237–1245PubMed

47.

Garvin S, Ollinger K, Dabrosin C (2006) Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231(1):113–122CrossRefPubMed

48.

Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB (2007) Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J 120(19):1672–1677PubMed

49.

Wu H, Liang X, Fang Y, Qin X, Zhang Y, Liu J (2008) Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia-induced factor-1 alpha expression in colon carcinoma cells. Biomed Pharmacother 62(9):613–621CrossRefPubMed

50.

Cao Z, Fang J, Xia C, Shi X, Jang BH (2004) Trans-3,4,5′-trihydroxystibene inhibits hypoxia-inducible factor 1 alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10(15):5253–5263CrossRefPubMed

51.

Park SY, Jeong KJ, Lee J, Yoon DS, Choi WS, Kim YK, Han JW, Kim YM, Kim BY, Lee HY (2007) Hypoxia enhances LPA-induced HIF-1α and VEGF expression: their inhibition by resveratrol. Cancer Lett 258:63–69CrossRefPubMed

52.

She Q, Bode AM, Ma W, Chen N, Dong Z (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-related protein kinases and p38 kinase. Cancer Res 61:1604–1610PubMed

53.

Heiss EH, Schilder YDC, Dirsch VM (2007) Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells. J Biol Chem 282(37):26759–26766CrossRefPubMed

54.

Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA (2007) Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28:282–293CrossRefPubMed

55.

Ou HC, Chou FP, Sheen HM, Lin TM, Yang CH, Huey-Herng Sheu W (2005) Resveratrol, a polyphenolic compound in red wine, protects against oxidized LDL-induced cytotoxicity in endothelial cells. Clin Chim Acta 364(1–2):196–204PubMed

56.

Szende B, Tyihák E, Király-Véghely Z (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32(2):88–92PubMed

57.

Wang XB, Huang J, Zou JG, Su EB, Shan QJ, Yang ZJ, Cao KJ (2007) Effects of resveratrol on number and activity of endothelial progenitor cells from human peripheral blood. Clin Exp Pharmacol Physiol 34(11):1109–1115PubMed

58.

Trapp V (2009) The design of a three-dimensional spheroidal model of tumor angiogenesis and its implementation in anti-angiogenesis studies. Dissertation, University of California

59.

Chen X, Aledia AS, Ghajar CM, Griffith CK, Putnam AJ, Hughes CCW, George SC (2009) Prevascularization of a fibrin-based tissue construct accelerates the formation of functional anastomosis with host vasculature. Tissue Eng 15(6):1363–1371CrossRef

60.

O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300PubMed

61.

Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thombospondin-1. Science 265:1582–1584CrossRefPubMed

62.

Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, Cote RJ (1997) Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 89(3):219–227CrossRefPubMed

63.

Blumenson LE, Bross ID (1976) A possible mechanism for enhancement of increased production of tumor angiogenic factor. Growth 40(3):205–209PubMed

64.

Shweiki D, Itin A, Soffer D, Keshet E (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398):843–845CrossRefPubMed

65.

Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R, Brady JN (1998) Phosphorylation of p53 serine increases interaction with CBP. J Biol Chem 273(49):33048–33053CrossRefPubMed

66.

She QB, Bode AM, Ma WY, Chen NY, Dong Z (2001) Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61(4):1604–1610PubMed

67.

Lin HY, Shih A, Davis FB, Tang HY, Martino LJ, Bennett JA, Davis PJ (2002) Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 168(2):748–755CrossRefPubMed

68.

Elliot PJ, Jirousek M (2008) Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 9(4):371–378

69.

Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventative agent. Cancer Epidemiol Biomarkers Prev 16(6):1246–1252CrossRefPubMed

70.

Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32(12):1377–1382CrossRefPubMed

Title: Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture
Authors: Valerie Trapp
Basmina Parmakhtiar
Vartan Papazian
Lyndsay Willmott
John P. Fruehauf
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Angiogenesis / Issue 4/2010
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-010-9187-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

The impact of EPLINα (Epithelial protein lost in neoplasm) on endothelial cells, angiogenesis and tumorigenesis

Comparative analysis of angiogenic gene expression in normal and impaired wound healing in diabetic mice: effects of extracorporeal shock wave therapy

Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane

Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model

Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page